Overview

• The slide-sized device replicates blood vessels, marrow cavities and bone lining and self-organizes when seeded with patient cells that generate their own structural proteins.
• High-resolution imaging on the chip tracks CAR T cells as they navigate vessels, engage leukemia cells and trigger a bystander effect among other immune cells.
• By tuning experimental conditions the platform has simulated remission, treatment resistance and relapse, revealing that fourth-generation CAR T cells outperform standard versions at lower doses.
• The system can be assembled in just half a day and supports two-week experiments, offering a much faster and more scalable alternative to traditional animal models.
• Investigators are developing a matrix-based analytical and integrative index to forecast therapy outcomes and advance personalized immunotherapy planning.